Table 2.
Post-transplant data. ° Peripheral blood lymphocyte count was available on day 28, 56, +84, +180, and +365 for all survivor patients. § Chimerism on peripheral blood was available for all patients alive without disease relapse. † Toxicities were graded according to standard National Cancer Institute Common Terminology Criteria for Adverse Events version 4.0. ‡ Hemorrhagic cystitis and cerebral hemorrhage.
| Post-Transplant Data (n = 85) | |
|---|---|
| Engraftment median time | |
| Neutrophils engraftment > 0.5 × 109/L | 14 days (range 11–32) |
| Platelets engraftment > 20 × 109/L | 16 days (range 10–201) |
| Peripheral Blood Lymphocyte count ° | |
| Day+28 Median (U/µL) | 400 (range 10–3640) |
| Day+56 Median (U/µL) | 1200 (range 250–5000) |
| Day+84 Median (U/µL) | 1200 (range 360–5000) |
| Day+180 Median (U/µL) | 1800 (range 400–4900) |
| Day+365 Median (U/µL) | 2100 (range 110–5600) |
| Chimerism § | |
| Day+28 | >97% of patients alive and not relapsed |
| Day+56 | >97% of patients alive and not relapsed |
| Day+84, +180, +365 | >97% of patients alive and not relapsed |
| CMV reactivation | |
| Incidence | 55 (65%) |
| Median day of reactivation | 37 (range 13–330) |
| Bloodstream infection during engraftment | |
| (day 0–26) | |
| Incidence | 14 (16%) |
| Sort of microorganism | |
| E. Coli | 5 (36%) |
| Pseudomonas aeruginosa | 4 (29%) |
| Klebsiella pneumoniae carbapenemase-producing | 3 (21%) |
| Klebsiella Oxytoca | 1 (7%) |
| Enterococcus Faecium | 1 (7%) |
| Invasive Fungal infection at 1 year | |
| Incidence | 3 (4%) |
| Toxicity (G3–G4) † | |
| Mucositis | 16 (19%) |
| Hemorrhage ‡ | 6 (7%) |
| Liver enzymes elevation | 5 (6%) |
| Sinusoidal obstruction disease (SOS) | 4 (5%) |
| Hypocalcemia | 1 (1%) |
| Hyperbilirubinemia | 1 (1%) |